Melinta Therapeutics, Inc. (NASDAQ:MLNT)
| 7.45 Delayed Data As of Apr 20 |  0.00 / 0.00%Today’s Change | 6.50 Today|||52-Week Range 24.25 | -52.85% Year-to-Date |
Latest MLNT News | Press Releases
No recent news for Melinta Therapeutics, Inc..
Today’s Trading
| Previous close | 7.45 |
| Today’s open | 7.35 |
| Day’s range | 7.15 - 7.63 |
| Volume | 120,831 |
| Average volume (3 months) | 164,038 |
| Market cap | $421.3M |
Data as of 4:00pm ET, 04/20/2018
Growth & Valuation
| Earnings growth (last year) | -11.96% |
| Earnings growth (this year) | +58.89% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -34.03% |
| P/E ratio | NM |
| Price/Sales | 7.82 |
| Price/Book | 0.77 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| SMMTSummit Therapeutics ... | +0.13 | +0.95% |
| VRNAVerona Pharma PLC | -0.19 | -1.13% |
| NTECIntec Pharma Ltd | +0.10 | +1.90% |
| ACRXAcelRx Pharmaceutica... | -0.07 | -3.09% |
Data as of 4:00pm ET, 04/20/2018
Financials
| Next reporting date | April 27, 2018 |
| EPS forecast (this quarter) | -$4.20 |
| Annual revenue (last year) | $18.0M |
| Annual profit (last year) | -$118.0M |
| Net profit margin | -654.76% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
President, Chief Executive Officer & Director Daniel Mark Wechsler |
CFO, Secretary & Principal Accounting Officer Paul Estrem |
Corporate headquarters New Haven, Connecticut |
Forecasts
